CSL (ASX:CSL) has had a rough three months with its share price down 17%. However, stock prices are usually driven by ...

Is this stock a healthy opportunity? Let’s have a look. The post Is the CSL share price a buy? Here's a top broker's view ...

Are CSL Ltd (ASX: CSL) shares a buy or a sell? Let's find out what one leading broker is saying about this blue chip ...

Morgan Stanley analyst David Bailey maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$313.00. The ...

CSL Limited's financial performance reveals not just growth but a commitment to future innovations. With a total revenue of $22.2 billion, the company allocated $1.43 billion—approximately 9.6% of its ...

It’s not Trump’s tariffs that could pressure the CSL share price, but a new high-level government appointee. Here’s why.

Investors are in panic as Australian drug companies could be the next victims in an expansion of the US trade war.

UBS analyst Laura Sutcliffe maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$310.00. The company’s ...

Australian biotech major CSL Limited (ASX: CSL) subsidiary CSL Behring today announced that it has successfully concluded ...

Recent trading sessions have been turbulent for CSL Ltd, with shares declining sharply amid mounting concerns surrounding international trade policies. After a fall of 1.7% on Friday and a further ...

Discover why CSL and WiseTech Global are emerging as potential buying opportunities despite recent market turbulence. Learn ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...